Is Alnylam Roche's 'second Genentech'?
The incoming CEO of Roche says he hopes that the company's partnership with Alnylam will create a "second Genentech" in the U.S. for the pharma giant. Alnylam opens up a "new front" in biotech, says Severin Schwan. Roche is paying $331 million up front to gain access to Alnylam's drug discovery technology. It's another sign of the steady convergence of biotech and pharma, with a product-hungry pharma world looking to biotechnology companies to supply the products of the future. It's also a key indicator of the thriving market for new deals.
- read the AFX report for more information
Relate Articles:
Roche shakes up R&D, eyes new buyouts. Report
Roche harnesses Alnylam's RNAi tech in $1B deal. Report
Genentech touts pipeline as doubts fester. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends